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OBJECTIVE—Approximately 25% of children and adolescents
with type 1 diabetes will develop diastolic dysfunction. This
defect, which is characterized by an increase in time to cardiac
relaxation, results in part from a reduction in the activity of the
sarco(endo)plasmic reticulum Ca
2+-ATPase (SERCA2a), the ATP-
driven pump that translocates Ca
2+ from the cytoplasm to the
lumen of the sarcoplasmic reticulum. To date, mechanisms re-
sponsible for SERCA2a activity loss remain incompletely charac-
terized.
RESEARCH DESIGN AND METHODS—The streptozotocin
(STZ)-induced murine model of type 1 diabetes, in combination
with echocardiography, high-speed video detection, confocal
microscopy, ATPase and Ca
2+ uptake assays, Western blots,
mass spectrometry, and site-directed mutagenesis, were used
to assess whether modiﬁcation by reactive carbonyl species
(RCS) contributes to SERCA2a activity loss.
RESULTS—After 6–7 weeks of diabetes, cardiac and myocyte
relaxation times were prolonged. Total ventricular SERCA2a pro-
tein remained unchanged, but its ability to hydrolyze ATP and
transport Ca
2+ was signiﬁcantly reduced. Western blots and mass
spectroscopic analyses revealed carbonyl adducts on select ba-
sic residues of SERCA2a. Mutating affected residues to mimic
physio-chemical changes induced on them by RCS reduced
SERCA2a activity. Preincubating with the RCS, methylglyoxal
(MGO) likewise reduced SERCA2a activity. Mutating an impacted
residue to chemically inert glutamine did not alter SERCA2a
activity, but it blunted MGO’s effect. Treating STZ-induced di-
abetic animals with the RCS scavenger, pyridoxamine, blunted
SERCA2a activity loss and minimized diastolic dysfunction.
CONCLUSIONS—These data identify carbonylation as a novel
mechanism that contributes to SERCA2a activity loss and di-
astolic dysfunction during type 1 diabetes. Diabetes 60:947–
959, 2011
M
ore than 12 million children and adolescents
worldwide have type 1 diabetes (1). In the
U.S., 1.2 million children have type 1 diabetes,
and ~30,000 new cases are diagnosed every
year (2). There is no known way to prevent type 1 di-
abetes, and exogenous insulin is needed to lower/regulate
blood glucose levels on a daily basis. Individuals with type 1
diabetes who are unable to tightly regulate their blood
glucose levels before and after meals also develop cardio-
vascular diseases, including heart failure, at rates 3–5t i m e s
higher that of the general population. To date, the patho-
genesis of this diabetic cardiomyopathy (DC) remains in-
completely deﬁned, and, as a result, therapeutic strategies
to prevent and/or slow its progression also remain limited.
One of the earliest clinical signs that DC is developing in
individuals with type 1 diabetes is that their hearts take
longer to relax between contractions (3,4). Although this
diastolic dysfunction is benign at rest, a sudden tachycar-
dia can precipitate arrhythmias, some of which are fatal. An
example of the latter is the devastating dead-in-bed syn-
drome that is triggered by nocturnal hypoglycemia-induced
tachycardia in ~6% of young type 1 diabetic patients (5).
Cardiac relaxation occurs in two sequential phases: an
early active phase that is initiated principally by the action
of sarco(endo)plasmic reticulum Ca
2+-ATPase (SERCA2a)
to return the evoked rise in cytoplasmic Ca
2+ to basal levels
and a later passive phase that is dependent on the disten-
sibility of the extracellular matrix (4). Using animal models,
several investigators have found reduced SERCA2a ac-
tivity during type 1 diabetes (6,7). Despite its central role
in diastole, mechanisms underlying SERCA2a activity
loss during type 1 diabetes remain incompletely deﬁned.
General explanations include a reduction in the expres-
sion arising from increased O-GluNAcylation (O-linked
N-acetylglucosamine) of its transcription factor Sp1, thyroid
hormone reductions, and from an increased association of
its intrinsic inhibitor protein, phospholamban (PLN) (8–12).
However, several laboratories, including ours, have found
only minimal changes in expression levels of SERCA2a,
PLN, and/or the phosphorylation status of PLN, especially
during the early stages of the syndrome or with less severe
experimental diabetes (i.e., blood glucose levels #20 mmol)
(13–17). Therefore, we rationalize that uncharacterized
mechanisms are at play that reduce SERCA2a activity dur-
ing early type 1 diabetes.
It has been known for some time that reactive carbonyl
species (RCS) are elevated in the serum and urine of
patients with type 1 diabetes as a result of increased
glucose and fatty acid oxidation, increased degradation
of ketotic products, and increased triose pathway ﬂux
(18–20). Expression of vascular adhesion protein (VAP)-1/
semicarbazide-sensitive amine oxidase (SSAO), an enzyme
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ORIGINAL ARTICLEthat synthesizes the potent RCS methylglyoxal, also was
found to be upregulated as early as 1 week after the onset
of diabetes (21). When in excess, RCS reacts with exposed
arginine, lysine, and histidine residues on proteins to form
carbonyl adducts by a process referred to as carbonylation
(22,23). In an earlier study (24), we found elevated levels
of carbonyl adducts on select basic residues of SERCA2a
isolated from the hearts of streptozotocin (STZ)-induced
diabetic rats. However, it was not clear whether these
adducts were functionally important or an epiphenomenon
of the diabetes. Therefore, the purpose of the current study
was to ascertain whether carbonyl adducts formed on
SERCA2a during diabetes impair its ability to transport Ca
2+.
RESEARCH DESIGN AND METHODS
Antibodiesand chemicals. SERCA2a and PLN antibodies were obtained from
Thermo Fisher Scientiﬁc (Boulder, CO) and Millipore (Rochester, NY),
argpyrimidine antibodies were obtained from JaiCA (Zhizuoka, Japan), and
VAP-1 (H-43), actin (
11C), and all secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Advanced glycation end prod-
ucts (AGEs), 3-deoxyglycosone/imidazolone, carboxymethyllysine (CML),
carboxyethyllysine, pentosidine, and pyralline were provided by Dr. Royji
Nagai. SSAO was assayed using SSAO assay kits (Cell Technology, Mountain
View, CA). Insulin pellets were obtained from LinShin Canada (Scarborough,
Canada). Other reagents and buffers used were of the highest grade com-
mercially available.
Induction and veriﬁcation of experimental type 1 diabetes. Animals used
in the study were approved by the institutional animal care and use committee
of the University of Nebraska Medical Center and adhered to American
Physiological Society’s guiding principles for animal research (25). Forty-eight
male SD rats were injected with freshly prepared STZ in cold 0.1 mol/L citrate
buffer, pH = 4.5 (45 mg/kg i.v., 0.2 mL). Thirty-two other rats also were injected
with a similar volume of citrate buffer only. Animals of similar weights and
disease status were housed at 22°C with ﬁxed 12-h light/12-h dark cycles with
30–40% relative humidity. Laboratory standard diet and tap water were given ad
libitum.
Treatment of diabetic animals. Two weeks after the STZ injection, STZ-
induced diabetic rats were randomly divided into three groups. One group was
treated with the RCS scavenger, pyridoxamine (PyD; 1.6 g $ kg
21 $ day
21), via
drinking water for 4–5 weeks and were labeled the PyD-D group (26).
A second group of STZ-induced diabetic animals was treated with insulin
(0.5 mm 3 5 mm insulin pellet inserted subcutaneously) for 2 weeks to attain
a euglycemic state (Ins-D group), starting 4–5 weeks after STZ injection. The
third group of diabetic animals remained untreated (D group). Control ani-
mals also were divided into two groups: one group was treated with PyD
(2.0 g $ kg
21 $ day
21 because they drank one-third less water) (PyD-C group)
(27) for 4–5 weeks, starting 2 weeks after the citrate buffer injection, whereas
the other group remained untreated (C group).
Establishing diastolic dysfunction
Pulse-wave echocardiography. At the end of the protocol, rats were
anesthetizedwithacepromazine/ketamine(0.3mLof2:5mixture),securedwith
tape in the supine position on a heated (37°C) pad, and maximal early (E) and
late (A) diastolic transmitral ﬂow velocities were measured using a Vevo 770
High Resolution In Vivo Micro Imaging System with a color ﬂow–guided, pulsed-
wave Doppler probe (716, 17.6-MHz; VisualSonics, Toronto, Canada).
In vivo hemodynamics. Basal and isoproterenol-induced heart rates and
rates of left-ventricular pressure decline (2dP/dt) were evaluated as described
earlier (28).
Myocytes isolation. Ventricular myocytes were isolated from rat hearts, as
described previously, using retrograde collagenase perfusion (17,28).
Myocyte function
Evoked Ca
2+ transients. Evoked Ca
2+ transients were measured using the
method described earlier (17). Ca
2+ transients were recorded at 0.5 Hz (10 V for
10 ms) and 2.0 Hz.
Contractile kinetics. Contraction also was measured as described earlier
(17), and contraction kinetics were measured at 0.5 Hz (10 V for 10 ms) and at
2.0 Hz.
Sarcoplasmic reticulum Ca
2+ load. Myocytes were loaded with Fura-2 AM
in DMEM-F12 medium containing 1.2 mmol/L Ca
2+, and sarcoplasmic re-
ticulum (SR) Ca
2+ load was assessed as described earlier (17).
Steady-state levels of SERCA2a, PLN, and VAP-1. Membrane vesicles
were prepared from ventricular tissues of hearts from C, D, Ins-D, PyD-C, and
PyD-D rats as described earlier (17,24). Western blot analyses were used to
determine steady-state SERCA2a, PLN, VAP-1 (the enzyme that synthesizes
methylglyoxal [MGO]), and glyoxalase-1 (the enzyme that degrades MGO)
levels using 10 mg vesicular proteins as described earlier (17,24,28).
Determination of carbonyl adducts
Western blots. Western blots using 80 mg vesicular proteins, 1:500–1,000
primary antibodies, and 1:5,000 secondary antibodies were used to de-
termine relative amounts of AGEs, argpyrimidine (methylglyoxal), CML,
carboxyethyllysine, 3-deoxyglycosone/imidazolone, pentosidine, and pyralline
antibodies on SERCA2a.
Mass spectrometry. SERCA2a was immunoprecipitated from membrane
vesicles using a commercially available polyclonal SERCA2a antibody, as per
the manufacturer’s instructions (Afﬁnity BioReagents, Boulder, CO). Immu-
noprecipitated SERCA2a was then puriﬁed from SDS-PAGE and digested with
trypsin, desalted, and separated into two aliquots. One aliquot was subjected
to matrix-assisted laser desorption ionization–time-of-ﬂight (MALDI-TOF) mass
spectrometry (24). The second aliquot was used to determine the amino acid
sequence of modiﬁed peptides using tandem mass spectrometry using nano-ﬂow
capillary liquid chromatography coupled with quadruple time-of-ﬂight mass
spectrometry (Micromass, Manchester, U.K.).
Determination of MGO levels in ventricular tissue. MGO levels were
assessed in left-ventricular tissue using the high-performance liquid chro-
matographic procedure described by Thornalley et al. (29), except that
2-methylquinoxaline was used as the internal standard.
Site-directed mutagenesis. Four residues on SERCA2a were investigated in
this study (R164, K476, K481, and R636) (see Fig. 1) because they were found to
be carbonylated in this and our previous study (24). Residues were mutated
singly and in combination to glycines to determine the impact of charge
neutralization, to tyrosines and tryptophans to assess the impact of charge
neutralization and increase in bulk (analogous to argpyrimidine and pyralline
adducts), and to glutamic acids to assess the impact of charge inversion
(analogous to CML or CML adducts) using QuikChange mutagenesis kits
(Stratagene, La Jolla, CA) with oligo primers. Residues also were mutated to
glutamines to blunt formation of MGO adducts. After mutations, plasmids
were transformed into competent HB101 cells, ampliﬁed in liquid cultures, and
puriﬁed using plasmid Maxi Prep (Qiagen, Valencia, CA), and mutations were
conﬁrmed using DNA sequencing. cDNA encoding human SERCA2a was
provided by Dr. David Mclennan (University of Toronto).
Expression of recombinant SERCA2 protein. Wild-type or mutant
SERCA2a cDNA (10–15 mg) was transfected into human embryonic kidney
(HEK)-293T cells (30–40% conﬂuency) using Ca
2+-phosphate and grown in
Petri dishes (100 mm) for 36–44 h. After this time, cells were harvested,
sonicated (4 3 6 s) in buffer (0.25 mol/L sucrose, 10 mmol/L histidine, pH 7.3)
and a protease inhibitor mix (1 mmol/L benzamidine, 2 mg/mL leupeptin, 2 mg/mL
pepstatin A, 2 mg/mL aprotinin, and 0.5 mmol/L phenylmethylsulfonyl ﬂuoride)
and centrifuged at 13,000 rpm for 3 min. Supernatants were collected, and
relative SERCA2a content was determined using serial-dilution Western blots.
HEK-293T cells were for expression and chosen because they express low
levels of endogenous SERCA2a and do not express PLN.
SERCA2 activity
Ca
2+ uptake assays (steps 1–6 of the post-Elbers cycle [E1→E2]).
Membrane vesicles were resuspended in 1 mL buffer (30 mmol/L Tris-HCl,
pH 7.0; 100 mmol/L KCl; 5 mmol/L NaN3; 5 mmol/L MgCl2; 0.15 mmol/L EGTA;
0.12 mmol/L CaCl2;1mCi
45Ca
2+; and 10 mmol/L potassium oxalate) and were
divided into 2 3 500-mL aliquots. One aliquot was incubated with a SERCA2a
inhibitor cocktail (10 mmol/L thapsigargin, 100 mmol/L ammonium molybdate,
and 0.05 mgb a ﬁlomycin) and the other remained untreated. Ca
2+ uptake
assays were conducted as described by Andersen (30,31) using Na2ATP to
initiate uptake. In assays involving rat heart membrane vesicles, 50 mmol/L
ryanodine was added to the incubation media for 10 min to inhibit or close the
ryanodine receptor Ca
2+ release channel.
Ca
2+-ATPase activity (steps 1–3 of the post-Elbers cycle). Wild-type and
mutated SERCA2a (equivalent amounts of proteins) were incubated in 500 mL
buffer (10 mmol/L HEPES, pH 7.3; 0.1 mol/L KCl; 5 mmol/L Mg
2+; 100 mmol/L
Ca
2+; 100 mmol/L EGTA; and 2.5 mmol/L Na2-ATP) and incubated for 20 min at
37°C in the presence and absence of the Ca
2+ ionophore, A23187 (2 mg/mL)
(30,31). After this time, reactions were stopped and the inorganic phosphate
generated from ATP hydrolysis was assessed using the malachite green col-
orimetric assay described previously (28).
Statistical analysis. Differences among values from each of the ﬁve groups
(groups C, D, Ins-D, PyD-C, and PyD-D) were evaluated with ANOVA using
Prism GraphPad. Data shown are means 6 SE. Results were considered sig-
niﬁcantly different if P , 0.05 (95% CI).
RESULTS
Animal characteristics and conﬁrmation of diastolic
dysfunction. The general characteristics of the animals
used in this study are listed in Table 1. After 6–7 weeks of
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istic reductions in early atrial-phase left-ventricular ﬁlling
velocity (E) and E-to-A ratio (Fig. 2A). In vivo hemody-
namics also showed a parallel increase in time to 50% re-
laxation (T50) (Fig. 2B). Two weeks of insulin therapy
initiated 4–5 weeks after the onset of diabetes blunted
decreases in blood ﬂow velocity during diastolic ﬁlling and
the E-to-A ratio (Fig. 2B) and T50 (Fig. 2B), establishing
that diastolic dysfunction was not a result of STZ toxicity,
per se, but rather diabetes.
Diabetes slows myocyte Ca
2+ transient decay and
myocyte relaxation. Figure 3A, left side, shows charac-
teristic prolongation in myocyte Ca
2+ transient decay time
induced by diabetes at a low stimulation frequency (0.5 Hz).
Rate and amplitude of Ca
2+ release also were reduced
(Table 1, left) probably because of the reduced SR Ca
2+ load
(17). Mean data from .50 cells from three rats per group
are shown in Table 1. Parallel reductions in contraction and
relaxation velocities as well as myocyte shortening also
were seen at 0.5 Hz (Fig. 3A, right side). Mean data are
shown in Table 1, right.
At the higher 2-Hz stimulation, ~9% of diabetic myocytes
(11 of 120) exhibited Ca
2+ alternans (Fig. 3B, second panel,
red line). In six of these 11 diabetic myocytes, the defect
in Ca
2+ reuptake was limited to a small segment of the
scanned region (~15 mmol/L) (Fig. 3B, second panel, white
arrows). Treating diabetic animals with insulin blunted the
prolongation in Ca
2+ transient decay time (Table 2). At the
FIG. 1. Schematic showing the locations of carbonyl adducts found on SERCA2a. The structure of SERCA2a was adapted from Dode et al. (36).
TABLE 1
General characteristics of animals
Parameter Control (C)
STZ-induced
diabetic (D)
Insulin-treated
STZ-induced
diabetic (Ins-D)
PyD-treated
control (PyD-C)
PyD-treated
STZ-induced
diabetic (PyD-D)
n 16 16 16 15 16
Body mass (g) 370.0 6 13.3 290.1 6 17.3* 324.0 6 7.5 397.6 6 12.9 273.5 6 15.6
Glycosylated hemoglobin (%) 4.1 6 0.1 7.2 6 0.1* 4.7 6 0.2 4.2 6 0.2 7.6 6 0.3
Blood glucose (mmol) 5.0 6 0.5 21.1 6 1.4* 8.1 6 2.1 4.9 6 1.1 20.1 6 1.6
Serum insulin (ng/mL) 1.02 6 0.21 0.31 6 0.03* 0.91 6 0.02 1.10 6 0.07 0.28 6 0.04
Serum SSAO activity
(units $ mL
21 $ min
21) 0.32 6 0.02 0.56 6 0.03* 0.35 6 0.06 0.22 6 0.01 0.39 6 0.02†
Serum T3 (ng/dL) 218.9 6 13.1 171.8 6 17.4* ND 209.7 6 20.4 174.8 6 10.4
Data are means 6 SE (n $ 15). *Signiﬁcantly different from control rats (P , 0.05). †Signiﬁcantly different from STZ-induced diabetic rats
(P , 0.05). ND, not done.
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ted contraction alternans (Fig. 3B, second panel, red line),
which was likely the consequence of Ca
2+ alternans.
Contraction kinetics of myocytes from euglycemic animals
were similar to that of control animals (Table 2).
SERCA2a activity is reduced independent of protein
levels. Minimal change in steady-state SERCA2a and
monomeric PLN proteins were found in rat ventricular tis-
sues after 6–7 weeks of diabetes (Fig. 4A). There was slight
decrease (,10%, P . 0.05) in pentameric (phospho-Ser16)
PLN. The ability of SERCA2a to hydrolyze ATP and trans-
port Ca
2+ (E1→E2)w e r e3 0 . 16 6.3% and 35.2 6 6.4% lower
in diabetic animals (Figs. 4B and C). Treating diabetic
animals with insulin did not alter steady-state SERCA2a
or PLN proteins, but it blunted SERCA2a activity loss.
Assessment of argpyrimidine and other carbonyl
adducts on SERCA2a during diabetes. The MGO-
derived argpyrimidine adduct was threefold higher on
SERCA2a from diabetic animals compared with controls
(Fig. 5A, upper autoradiogram). Other adducts such
as AGEs, CML, pentosidine, and pyralline also were in-
creased 1.2- to 5-fold during diabetes (Fig. 5A). The amount
of immunoreactive 3-deoxyglucosone/imidazolone and
carboxyethyllysine did not change on SERCA2a after
6–7 weeks of diabetes.
Mass spectrometry (MALDI-TOF and tandem) were then
used to identify and conﬁrm the locations of carbonyl
adducts on SERCA2a. As shown in Fig. 5B, alignment of
MALDI-TOF data revealed the presence of an M+1 peak at
2485.12 Da in the diabetic sample but not in control or
insulin-treated SERCA2a samples. Our Perl algorithm (32)
suggests that this mass could arise from a pentosidine
adduct cross-linking K460 (452MNVFDTELKGLSK464)i nt h e
nucleotide (N) domain and R636 (629GTAVAIRR637)i nt h e
phosphorylation (P) domain. Fragmentation of the 2,485.12
Da peak afforded M+1 peaks at 950.4286, 708.3023, 607.2547,
492.2273, 347.2286, 246.0902, and M+1 peaks at 230.1132,
329.1814, 400.2190, and 513.3027, corresponding to b and y
M+1 ions from MNVFDTELKGLSK and M+1 b ions from
GTAVAIRR, respectively (Fig. 5C). The combination MALDI-
TOF followed by tandem mass spectrometry conﬁrmed
argpyrimidine on R164, pyralline on K476 and K481, and
CML adduct on R636.
Steady-state levels of VAP-1, MGO, and glyoxalase-1
in rat heart during diabetes. Because the argpyrimidine
adduct arises from elevation in MGO, we then sought to
FIG. 2. A, upper panel: Representative pulse-wave echocardiograms of hearts from control (C), STZ-induced diabetic (D), and insulin-treated STZ-
induced diabetic (Ins-D) rats. After securing the rats with tape in the supine position on a heated (37°C) pad, maximal early (E) and late (A)
diastolic transmitral ﬂow velocities were measured using a color ﬂow–guided, pulsed-wave Doppler probe (716, 17.6 MHz). Values in the lower
panels are means 6 SE (n ‡ 8). B: Mean time to 50% relaxation obtained from in vivo hemodynamic studies of control (C), STZ-induced diabetic
(D), and insulin-treated STZ-induced diabetic rats before and after isoproterenol stimulation. Values are means 6 SE (n ‡ 8). *Signiﬁcantly
different from control rats (P < 0.05). **Signiﬁcantly different from STZ-induced diabetic rats (P < 0.05). (A high-quality color representation of
this ﬁgure is available in the online issue.)
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950 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgFIG. 3. A, left side: Representative line-scan images of a single electrically evoked global Ca
2+ transient and contraction kinetics (right side)o f
ventricular myocyte from control (C) and STZ-induced diabetic (D) rats. Values shown in the lower panel are means 6 SE for n > 50 cells.
*Signiﬁcantly different from control rats (P < 0.05). B, left side: Consecutive evoked Ca
2+ transients (‡20) in ventricular myocytes isolated from
control (C), STZ-induced diabetic (D), and insulin-treated STZ-induced diabetic (Ins-D) rat hearts stimulated at 2 Hz. B, right side: Consecutive
evoked contractions (‡20) of ventricular myocytes isolated from control (C), STZ-induced diabetic (D), and insulin-treated STZ-induced diabetic
(Ins-D) rat hearts stimulated at 2 Hz. Black arrows indicate application of ﬁeld stimulation (2 Hz), and red lines indicate abnormal Ca
2+ transients
and contractions. White arrows (left panel) represent variation in Ca
2+ decay time along the scanned segment. (A high-quality digital represen-
tation of this ﬁgure is available in the online issue.)
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sizes and the enzyme that degrades MGO (i.e., VAP-1 and
glyoxalase-1) were altered in ventricular tissues during di-
abetes. Consistent with the increase in activity of its soluble
form SSAO (Table 1), the steady-state level of membrane-
bound VAP-1 was ~threefold higher in ventricular homo-
genates and myocytes from STZ-induced diabetic rats
(Fig. 6A). Only the monomeric form of VAP-1 (84 kDa) was
detected in these studies, probably because of denaturing
conditions used to run polyacrylamide gels. Glyoxalase-1
also was increased threefold in left-ventricular myocytes
during diabetes (Fig. 6B). MGO levels were twofold higher
in ventricular homogenates from STZ-induced diabetic rats
(8.0 6 1.2 mmol/L per 200 mg tissue in STZ-induced diabetic
rats vs. 3.8 6 0.5 mm o l / Lp e r2 0 0m gi nc o n t r o l s ) .
Assessing the importance of amino/azido moieties
o na m i n oa c i dr e s i d u e so fS E R C A 2 af o u n dt ob e
carbonylated during diabetes. Because SERCA2a under-
goes a series of timed conformational changes to hydrolyze
ATP and transport Ca
2+ (33), adducts like pentosidine, which
cross-link intra- and interdomain residues, will likely impair
the rate of conformation change and the ability of SERCA2a
to translocate Ca
2+ from the cytoplasm to the lumen of the SR.
What remains uncertain is whether non–cross-linking adducts,
such as argpyrimidine, CML, and pyralline, also will do the
same; if they do, are their effects on SERCA2a function resi-
due and adduct dependent?
To date, chemical methods to insert a speciﬁc carbonyl
adduct onto a speciﬁc amino acid without disrupting the
tertiary structure of SERCA2a are unavailable. Because
TABLE 2
Ca
2+ transient parameters for myocytes from control, STZ-induced diabetic, insulin-treated STZ-induced diabetic, PyD-treated control,
and PyD-treated STZ-induced diabetic rat hearts stimulated at 2 Hz
Parameter
Myocyte Ca
2+ transients
C D Ins-D PyD-C PyD-D
n 118 120 108 101 119
Rate of Ca
2+ rise (fu/s) 78.8 6 9.4 50.4 6 1.1* 76.4 6 2.1† 73.6 6 6.2 64.0 6 2.3†
Peak Ca
2+ amplitude (fu) 3.9 6 0.2 2.5 6 0.1* 4.1 6 0.1† 3.4 6 0.2 3.3 6 0.2†
T50 decay (ms) 286.5 6 10.1 730.1 6 12.5* 320.1 6 15.5† 229.6 6 10.8 402.4 6 20.1†
Parameter
Myocyte contractibility
C D Ins-D PyD-C PyD-D
n 120 123 101 94 116
Cell length (mm) 111.1 6 3.8 115.8 6 2.8 112.1 6 2.0 115.7 6 4.3 114.6 6 4.2
Contraction velocity (mm/s) 178.1 6 7.8 110.8 6 5.3* 139.7 6 6.9† 174.5 6 4.2 149.2 6 3.1†
Percentage cell shortening 13.5 6 0.5 10.7 6 0.5* 11.5 6 0.1† 11.7 6 1.1 11.8 6 0.2†
Relaxation velocity (mm/s) 148.8 6 8.3 103.9 6 5.9* 127.2 6 5.9† 156.1 6 6.6 132.2 6 4.2†
Time to 50% shortening (ms) 52.6 6 0.6 69.3 6 1.6* 53.6 6 0.5† 56.1 6 1.8 59.1 6 1.2†
Time to 50% relaxation (ms) 281.1 6 5.5 338.9 6 7.9* 291.0 6 5.2† 260.3 6 3.6 300.1 6 6.2†
Myocyte Ca
2+ transients: data are means 6 SE (n $ 100 cells). Myocyte contraction: Data are means 6 SE (n $ 94 cells). Contractile
properties of myocytes from control (C), STZ-induced diabetic (D), insulin-treated STZ-induced diabetic (Ins-D), PyD-treated control (PyD-C),
and PyD-treated STZ-induced diabetic (PyD-D) rats stimulated at 2 Hz. *Signiﬁcantly different from control rats (P , 0.05). †Signiﬁcantly
different from diabetic rats (P , 0.05).
FIG. 4. A: Representative autoradiogram showing relative levels of SERCA2a, monomeric, and pentameric (Ser16) PLN protein in whole-heart
homogenate from control (C), STZ-induced diabetic (D), and insulin-treated STZ-induced diabetic (Ins-D) rats. The graph below shows the relative
levels of SERCA2a protein. B: The ability of SERCA2a from control (C), STZ-induced diabetic (D), and insulin-treated STZ-induced diabetic (Ins-
D) rats to transport Ca
2+ (E1→E2). The graph shows means 6 SE in n ‡ 7 different preparations. C:C a
2+-ATPase activity of SERCA2a from control
(C), STZ-induced diabetic (D), and insulin-treated STZ-induced diabetic (Ins-D) rats. The graph shows means 6 SE in n ‡ 5 different preparations.
*Signiﬁcantly (P < 0.05) different from control rats. **Signiﬁcantly (P < 0.05) different from STZ-induced diabetic rats.
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bulk, and 3) in some cases changes the free basic group to
an acidic moiety, we reasoned that site-directed muta-
genesis could provide insights into the role these basic
amino acids are playing in the overall functioning of
SERCA2a and, by extension, the impact physio-chemical
changes induced on them by carbonylation will have on
the ability of SERCA2a to transport Ca
2+. Three of four
residues investigated in this study (K476 and K481 within
the N domain and R636 within the P domain) are exposed
to the aqueous medium, whereas the other, R164, is lo-
cated within the actuator (A domain) and away from the
aqueous environment ([34], also see Fig. 1).
Neutralizing basic charges on R164 and K481 by con-
verting them to glycines signiﬁcantly reduced the ability of
SERCA2a to transport Ca
2+ at all time points, indicating
that these amino groups play crucial roles in SERCA2a
function (Fig. 7A and C). Neutralizing basic charges on
K476 and R636 had minimal impact on the ability of
SERCA2a to transport Ca
2+ within the ﬁrst 10 min (Fig. 7B
and D). However, as time progressed, the activities of
these mutants were reduced, suggestive of “run down.”
Neutralizing the basic charge and increasing hydrophilic
bulk on R164 and R636 by converting them to tyrosines
signiﬁcantly reduced the ability of SERCA2a to transport
Ca
2+ at all time points (Fig. 7A and D). Mutating K476 and
Western Blots     MALDI-TOF showing Pentosidine adduct
(Lys460 and  Arg636 in diabetic)
     MS-MS spectra confirming peptides
with Lys460 and  Arg636
AB
C
Argpyrimidine
Pyralline
Carboxymethyllysine
Pentosidine
Imidazolone/
3-deoxyglucosone
Carboxyethyllysine
β-actin
AGEs
C D 
0
0
%
2472.00 2473.02
2472.04 2473.01
2474.00
2486.11 2487.09
2470.0 2465.0 2475.0 2480.0 2485.0 2490.0 2495.0
100
%
100
%
100
0
2472.01 2473.00
2473.98
m/z
m/z
m/z
2485.12
CONTROL (C)
STREPTOZOTOCIN-INDUCED-DIABETIC (D)
INSULIN-TREATED STREPTOZOTOCIN 
TOF LD+ 100
TOF LD+ 96
TOF LD+ 102
-INDUCED DIABETIC (Ins-D)
200 300 400 500 600 700 800 900 1000 1100
0
10
20
30
40
50
60
70
80
90
100
230.11+1
246.09+1
329.18+1
347.23+1
400.22+1
513.30+1
492.22+1
607.25+1 708.30+1
950.43+1
476.21+2
1200
m/z
R
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
M  N  V  F  D  T  E  L K  G  L  S  K
y3
b7 b8 b2 b4 b5
G  T  A  V  A  I   R  R
b3’ b4’ b5’ b6’
b3’
+1
b4’
+1
b5’
+1
b6’
+1
b2
+1
b4
+1
b5
+1
b7
+1
b8
+1
b8
+2
y3 
+1
FIG. 5. A: Representative autoradiograms of carbonyl adducts on SERCA2a isolated from control (C) and STZ-induced diabetic (D) rats. Immu-
noblots were obtained using 75–100 mg of membrane vesicles using argpyrimidine, AGEs, 3-deoxyglycosone/imidazolone, CML, carboxyethyllysine,
pentosidine, pyralline, and actin as the primary antibodies (1:500–1,000 dilution) in Western blot assays. Data shown are consistent in all four
experiments performed using different membrane preparations. B, upper panel: Alignment of a segment of MALDI-TOF mass spectra obtained
following trypsin digestion of SERCA2a from control (C), STZ-induced diabetic (D), and insulin-treated STZ-induced diabetic (Ins-D) rats. An M+1
peak is present at 2,485.12 Da in diabetic samples but not in the others. B, lower panel: Tandem data corresponding to the M+1 and M+2 peaks
obtained after fragmentation of peak 2,485.12 Da. Data obtained suggests that 2,485.12 Da corresponds to a pentosidine adduct between K460
(452MNVFDTELKGLSK464) in the nucleotide (N) domain and R636 (629GTAVAIRR637) in the phosphorylation (P) domain, consistent with our
PERL script prediction.
C.H. SHAO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 953K481 to tyrosines minimally impacted the ability of SERCA2a
to transport Ca
2+ within the ﬁrst 10 min (Fig. 7B and C).
However, as pumping time increased, Ca
2+ transport rates
declined. Mutating residues R164, K476, K481, and R636 to
tryptophan to mimic charge neutralization and an increase
in hydrophobic bulk signiﬁcantly reduced the ability of
SERCA2a to transport Ca2+ (Fig. 7A–D). Inverting the amino/
azide groups on R164, K476, K481, and R636 to acidic moi-
eties signiﬁcantly reduced the ability of SERCA2a to trans-
port Ca
2+ (Fig. 7A–D). Neutralizing the charge, increasing
bulk, or inverting the charge on two or more residues si-
multaneously signiﬁcantly reduced the ability of SERCA2a to
transport Ca
2+ (Fig. 7E). HEK-293T cells expressed full-
length wild-type and SERCA2a proteins (Fig. 7F).
To gain further insights into the mechanisms respon-
sible for their altered Ca
2+ transport, we also assessed the
ability of SERCA2a to hydrolyze ATP. Altering the basic
moiety and/or increasing bulk on K476 reduced its ability
to hydrolyze ATP, in agreement with reduced Ca
2+ uptake
data (Fig. 8G). Mutating K481 to tyrosine did not affect
the ability of SERCA2a to hydrolyze ATP, but the G, W,
and E mutants did, in agreement with their reduced ability
to transport Ca
2+ (Fig. 7H). Neutralizing the azide moiety
on R636, per se, had no impact on the ability of SERCA2a
to hydrolyze ATP. However, when bulk is also added, the
rate at which SERCA2a hydrolyzes ATP was reduced
(Fig. 7I). Collectively, these data suggest that carbonyla-
tion at K476, K481, and R636 reduces SERCA2a activity
by impairing its ability to hydrolyze ATP (steps 1–3o ft h e
post-Elbers cycle).
Protecting SERCA2a from the actions of methylglyoxal.
If the amino/azido groups on R164, K476, K481, and R636
are indeed important for SERCA2a activity, then pre-
venting them from undergoing carbonylation should blunt
SERCA2a activity loss.
Mutating impacted residues to unreactive glutamines.
Glutamine mutations initially were created and conﬁrmed on
R164 and R636 because the arginine moieties on these res-
idues are known to readily form argpyrimidine adducts with
MGO. However, we were unable to express signiﬁcant
quantities of R164Q and R636Q in either HEK-293T, CV-1
(simian) in origin and carrying the SV40 (COS) and Chinese
hamster ovary (CHO) cells for functional studies. MGO also
can form argpyrimidine adducts by utilizing adjacent amine
moieties (35). Because K480 and K481 are adjacent lysines
(36), this prompted us to synthesize the K481Q mutant to
disrupt the adjacent amine conﬁguration and assess whether
this change can blunt the action of MGO.
When transfected into HEK-293T cells, we found that both
wild-type and the K481Q mutant expressed similar amounts
of full-length SERCA2a protein (Fig. 8A, upper autoradio-
gram). The K481Q mutant also transported Ca
2+ (Fig. 8A,
graph below) and hydrolyzed ATP (Fig. 8B) in a manner
similar to that of wild-type SERCA2a, establishing that the Q
mutation did not affect the normal function of SERCA2a.
Having established that the K481 mutation did not alter
SERCA2a activity, we then sought to determine whether it
can blunt MGO action. Preincubating wild-type SERCA2a
for 20 min at 37°C with 1 mmol/L freshly synthesized MGO
(equivalent to the amount found in the serum of healthy
individuals) (26) potentiated the ability of SERCA2a to
transport Ca
2+ (Fig. 8C). Preincubation with higher MGO
(5–500 mmol/L, equivalent to the amount found in the se-
rum of diabetic patients) (26,37), dose-dependently reduced
the ability of SERCA2a to transport Ca
2+. Interestingly, the
K481Q mutant was resistant to the action of MGO (Fig. 8C),
and Western blots indicate that this protection resulted di-
rectly from reduced formation of argpyrimidine (Fig. 8C,
middle autoradiogram).
Scavenging RCS in diabetic animals using PyD. The
vitamin B6 congener PyD is a potent scavenger of RCS
(26), and it recently was shown to clinically reduce ne-
phropathy in patients with type 1 and type 2 diabetes (38).
We tested whether this compound also is capable of re-
ducing carbonylation of SERCA2a and minimizing di-
astolic dysfunction. Treatment of STZ-induced diabetic
animals with PyD did not alter blood serum glucose levels,
but it blunted serum SSAO activity (Table 1). PyD treat-
ment also blunted increases in left-ventricular pressure
and cardiac relaxation times (Fig. 9A) and increases in
FIG. 6. A: Representative autoradiograms for VAP-1 in whole-heart homogenates (upper panel) and ventricular myocytes (lower panel) from
control (C) and STZ-induced diabetic (D) rats. The graph below shows means 6 SE in n ‡5 different preparations. B: Representative autora-
diogram for glyoxalase-1 in ventricular myocytes isolated from control (C) and STZ-induced diabetic (D) rat hearts. The graph below shows
means 6 SE for n ‡7 preparations. *Signiﬁcantly (P < 0.05) different from control.
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2+ transient decay and relaxation times (Fig.
9B; Table 2). PyD treatment also reduced expression of
VAP-1 (Fig. 9C), formation of argpyrimidine and other
carbonyl adducts on SERC2a (Fig. 9D), and blunted its
activity loss without altering its expression (Fig. 9E).
DISCUSSION
In the current study, we demonstrate for the ﬁrst time that
by changing the charge and/or size of multiple critical basic
moieties, carbonylation reduces the ability of SERCA2a to
translocate Ca
2+ from the cytoplasm to the lumen of the
FIG. 7. A–D: The impact of a single mutation to neutralize charge (K/R→G), simultaneously neutralizing charge and increasing hydrophilic bulk
(K/R→Y), simultaneously neutralizing charge and increasing hydrophobic bulk (K/R→W), and inverting charge (K/R→E) on the ability of SERCA2a
to transport Ca
2+ (E1→E2). E: The impact of simultaneously neutralizing charge and increasing bulk on multiple residues on the ability of
SERCA2a to transport Ca
2+ (E1→E2). F: Representative autoradiograms for relevant SERCA2a mutants (upper band), emphasizing that changes
in activities observed were not a result of degradation of the SERCA2a protein. The lower band represents b-actin. G–I: The impact of neutralizing
charge and/or increasing bulk on amino acid residues 476, 481, and 636 on the ability of SERCA2a to hydrolyze ATP (steps 2–3 of the post-Elber’s
cycle), respectively. Graphs are means 6 SE from n = 4 experiments. *Signiﬁcantly (P < 0.05) different from wild type.
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of SERCA2a. In fact, in this study SERCA2a (and PLN)
proteins remained essentially unchanged even though se-
rum the T3 level was reduced by 21% during diabetes. Data
from the present and our earlier study (24) also suggest
that RCS does not react indiscriminately with all available
basic moieties on SERCA2a. Some residues (e.g., R164,
K476, K481, and R636) are more susceptible to carbonyl-
ation than others. Although the reason for this selectivity is
unclear at this time, the electronic environment of the
speciﬁc amino acid residue or groups of amino acids may
be a contributing factor.
We also found that the amount and location of carbon-
ylation dictates the impact it will have on SERCA2a func-
tion. With low levels of carbonylation (incubation with 1
mmol/L MGO), SERCA2a activity is actually enhanced.
Adachi et al. (39) also showed that low levels of peroxy-
nitrite oxidation resulted in gain of function of smooth-
muscle SERCA. However, which residues of SERCA2a are
hypersensitive to this low level of MGO remain unknown
at this time. Concentrations of MGO $5 mmol/L dose-
dependently reduced the ability of SERC2a to transport
Ca
2+, which is consistent with the notion that carbonyla-
tion at multiple sites is needed to reduce its activity.
Neutralizing the charge and increasing hydrophilic bulk
on residues exposed to the aqueous environment (K476,
K481, and R636) minimally impacted the ability of SERCA2a
to transport Ca
2+ during short-duration pumping. How-
ever, neutralizing the charge and increasing hydrophilic
bulk at R164, which resides away from the aqueous envi-
ronment, negatively impacted the ability of SERCA2a to
transport Ca
2+. Based on the work of Andersen (30,31) and
Clausen et al. (40), carbonylation of A domain R164 could
be uncoupling ATP hydrolysis from calcium transport.
Switching the polarity of the charge on R164, K476, K481,
and R636 from basic to acidic resulted in SERCA2a activity
loss, indicating that these amino/azide moieties are integral
for the function of SERCA2a.
Using membrane vesicles, we found an aggregate two-
to ﬁvefold increase in carbonyl adducts on SERCA2a
during diabetes. However, these data do not reveal the
extent to which a speciﬁc SERCA2a molecule becomes
carbonylated during diabetes and whether a few defective
SERCA2a molecules are sufﬁcient to negatively impact the
overall Ca
2+ transient integrity. To address this question,
we resorted to using confocal microscopy in the line-scan
mode. In ~10% of diabetic myocytes investigated, the in-
crease in time to Ca
2+ transient decay was not prolonged
throughout the entire scanned region but limited to a small
segment (Fig. 3B, left side, second panel, white arrows).
We interpret this data to mean that some SERCA2a mol-
ecules are defective, whereas others are not. Interestingly,
when these myocytes were stimulated at 2 Hz, Ca
2+ alter-
nans were observed (Fig. 3B, left side, second panel, red
line). In some diabetic animals we also observed cardiac
ventricular ﬁbrillation following isoproterenol injection
(data not shown), but the speciﬁc causes of this remain
unclear. Because Ca
2+ alternans is an underlying cause for
ventricular arrhythmias, these data also suggest that in-
creased carbonylation of SERCA2a may be contributing to
tachycardia-induced ventricular arrhythmias during di-
abetes. However, it should be pointed out that defects in
other SR Ca
2+-cycling proteins, such as type 2 ryanodine
receptor and type 2 calsequestrin also may be contributors
(41,42). Based on the data from this and an earlier study
(17), we speculate that perturbation in myocyte intracellular
FIG. 8. A: Relative expression levels of wild-type SERCA2a and the K481Q SERCA2a mutant in HEK-293T cells (upper autoradiogram) and the
ability of these proteins to transport Ca
2+ (A, graph) and hydrolyze ATP (B). C: K481Q mutation blunted the ability of MGO to reduce the ability
of SERCA2a to transport Ca
2+ (E1→E2). For the latter, wild-type and K481Q SERCA2a proteins were incubated in buffer with varying concen-
trations of MGO (0–500 mmol/L) for 20 min at 37°C. At the end of this time,
45Ca
2+ and ATP were added, and after 20 min samples were ﬁltered. The
amount of
45Ca
2+ remaining on the ﬁlter papers was used as an index of the ability of SERCA2a to transport Ca
2+. Western blot analyses also were
conducted on wild-type and K481Q samples incubated with 100, 300, and 500 mmol/L MGO to determine the extent of the argpyrimidine adduct (C,
middle autoradiogram). Western blots also were performed using SERCA2a and actin primary antibodies to ensure equivalent protein load.
Values are means 6 SE in n ‡3 different preparations. *Signiﬁcantly (P < 0.05) different from wild type.
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956 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgFIG. 9. A: Mean –dP/dt (rate of left-ventricular pressure decline) and time to 50% relaxation obtained from in vivo hemodynamic studies of STZ-
induced diabetic (D), PyD-treated control (PyD-D), and PyD-treated STZ-induced diabetic (PyD-D) rats before and after isoproterenol stimula-
tion. Values shown are means 6 SE (n ‡ 8). *Signiﬁcantly different from diabetic (P < 0.05) rats. B, left side: Consecutive evoked Ca
2+ transients
(‡20) in ventricular myocytes isolated from D, PyD-C, and PyD-D rat hearts stimulated at 2 Hz. B, right side: Consecutive contractions (‡20) of
ventricular myocytes isolated from D, PyD-C, and PyD-D rat hearts stimulated at 2 Hz. Black arrows indicate the application of ﬁeld stimulation
(2 Hz), and red lines indicate abnormal Ca
2+ transients and contractions. White arrows (left panel) represent the variation in Ca
2+ decay time
along the scanned segment. C: Autoradiogram for relative levels of VAP-1 in hearts from D, PyD-C, and PyD-D rats. D: Representative auto-
radiograms for carbonyl adducts on SERCA2a from D, PyD-C, and PyD-D rats. Standard Western blots were used for these studies using 75–100 mg
of membrane vesicles. D also shows alignment of a segment of MALDI-TOF mass spectra obtained following trypsin digestion of SERCA2a from D,
PyD-C, and PyD-D rats. M+1 peak at 2,485.12 Da seen in diabetic samples was not present after PyD treatment. E: Relative levels of SERCA2a
expression in ventricular tissues from D, PyD-C, and PyD-D rats. The graph below shows the ability of SERCA2a from D, PyD-C, and PyD-D rat
hearts to transport Ca
2+. Values shown are means 6 SE in n ‡7 different preparations. *Signiﬁcantly (P < 0.05) different from diabetic rats.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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2+ cycling arising from defects in SERCA2a and type 2
ryanodine receptor activities may be contributing to noc-
turnal hypoglycemia–induced ventricular arrhythmia and
the resultant dead-in-bed in young type 1 diabetic patients.
Having established that carbonyl adducts are functionally
important, we then proceeded to assess whether preventing
the formation of these adducts could minimize SERCA2a
activity loss and, by extension, diastolic dysfunction, in
vitro and in vivo. As indicated above, in vitro studies MGO
(5–500 mmol/L) dose-dependently reduced the ability of
SERC2a to transport Ca
2+. Mutating K481 to a glutamine to
prevent MGO from forming argpyrimidine with the adjacent
amino residues on K480 and K481 blunted the ability of
MGO to reduce SERCA2a activity loss. We also showed that
treating STZ-induced diabetic animals with the RCS scav-
enger PyD blunted carbonylation of SERCA2a and the di-
astolic dysfunction induced by diabetes. These data further
strengthen the notion that carbonylation is an important
mechanism underlying diabetic cardiomyopathy.
Another novel ﬁnding of the current study is that although
expression of the MGO-degrading enzyme glyoxalase-1
is elevated in rat ventricular myocytes during diabetes,
this increase was not sufﬁcient to reduce formation of
argpyrimidine adducts on SERCA2a. In fact, we measured
and found MGO levels to be twofold higher in ventricular
tissues from STZ-induced diabetic rats compared with
ventricular tissues from control animals. It should also be
pointed out that although this study focused on the impact
of MGO on SERCA2a, MGO also is likely to react with and
alter the function of other intracellular, long-lived proteins,
including type 2 ryanodine receptors (43). Another in-
teresting ﬁnding of the current study is that treatment with
PyD blunted the increase in cardiac VAP-1 induced by di-
abetes. The latter is extremely exciting because it sug-
gests, for the ﬁrst time, that MGO and other RCS may
be potentiating the expression of VAP-1/SSAO by a feed-
forward mechanism.
In conclusion, this study demonstrates, for the ﬁrst time,
that carbonylation is an important mechanism that con-
tributes to SERCA2a activity loss and diastolic dysfunc-
tion in a rat model of type 1 diabetes. These ﬁndings also
have implications beyond that of type 1 diabetes. Elevated
levels of carbonylated proteins also are found in patients
with type 2 diabetes, congestive heart failure, and renal
failure (44–50). Increasing expression of proteins including
SERCA2a without lowering carbonyl stress is likely to only
transiently blunt diastolic dysfunction during diabetes be-
cause newly expressed SERCA2a proteins will subsequently
undergo carbonylation (51). We propose scavenging RCS
as an adjunct therapeutic strategy for slowing diastolic
dysfunction during type 1 diabetes.
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